Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icotinib - Zhejiang Betta Pharma

Drug Profile

Icotinib - Zhejiang Betta Pharma

Alternative Names: BPI-2009; BPI-2009C; BPI-2009H; Conmana; Icotinib hydrochloride

Latest Information Update: 17 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beta Pharma
  • Developer Beta Pharma; Betta Pharmaceuticals Co Ltd; Zhejiang Betta Pharma
  • Class 3-ring heterocyclic compounds; Alkynes; Antineoplastics; Crown ethers; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Brain metastases; Lung cancer; Nasopharyngeal cancer; Neurofibromatosis 2; Oesophageal cancer; Psoriasis
  • No development reported Pancreatic cancer

Most Recent Events

  • 17 Aug 2021 Biomarkers information updated
  • 17 Aug 2021 Betta Pharmaceuticals in collaboration with The First Affiliated Hospital of Xiamen University plans a phase II trial for Non-small cell lung cancer (First-line therapy, Combination therapy, Late-stage disease, Metastatic disease) (PO) (NCT05007938)
  • 04 Jun 2021 Efficacy and adverse event data from the phase II ICOMPARE trial in Non-small cell lung cancer presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top